Olleyes’ New VisuALL Revolutionizes Eye Care
Portable Device Uses Artificial Intelligence (AI) and Virtual Reality (VR) to Make Eye Evaluation Faster and More Reliable
SUMMIT, N.J., Sept. 10, 2020 — Olleyes, a medical device company developing mobile and home-based diagnostic products for eye disorders, is making eye care more productive and personalized with VisuALL VRP— a portable visual care testing platform, which currently includes visual field and visual acuity testing. The VisuALL leverages virtual reality (VR), artificial intelligence (AI), and augmented technology to enable eye-care providers to remotely monitor common eye diseases.
Visual field testing is critical to the diagnosis and monitoring of patients with glaucoma and neuro-ophthalmic diseases. In the past, providers have had to rely on large and cumbersome devices that require patients to maintain fixation for several minutes. The portable headset device accommodates a patient’s physical needs and allows providers to adhere to current COVID-19 health and safety protocols while increasing productivity.
Discover how Olleyes’ VisuALL is reshaping eye care: youtube.com/watch?v=JFiiNcVWhdo
“At Olleyes, our mission is to make eye care productive and personalized. We have created the VisuALL VRP to change the time consuming and uncomfortable test taking status quo of ocular health testing. The compact design allows providers to increase their productivity by using multiple devices at once,” states Dr. Alberto Gonzalez, CEO.
The VisuALL system is composed of the virtual reality headset and Olleye’s proprietary software — accessed from a cell phone, tablet, or computer, allowing providers to test patients anywhere and in any position. The lightweight headset (0.3 kg) provides patients unprecedented freedom of movement.
- Productivity. The VisuALL is an intuitive platform allowing providers to control more than one device at a time easily.
- Portability. The small, lightweight VisuALL can easily be transported to any testing site in the office or home.
- Comfort & Ergonomic Design. Patients can be tested in any position. While the hygienic face cushion is easily disinfected and comfortable on the patient’s face.
- Ambient Control. The efficient control of lighting conditions allows testing to be performed in any office location, even a fully illuminated waiting room.
The VisuALL was validated at the Wallis Eye Hospital in a cross-sectional reference study. The study compared the VisuALL with the commonly used Humphrey Perimeter. Data from the pilot study shows the VisuALL Field Analyzer was as good as, if not better than the Humphrey.
In addition to the pilot study, Olleyes measures up to expectations from current eye care providers. Dr. Marc Bloomenstein, OD, recently praised the VisuALL in an article in Optometry Times, “In April 2020, I started engaging patients in this visual field analyzer from the chair in the lane, the waiting room, and, for a few patients, at their car. Sadly, our most vulnerable patients for COVID-19 are also our highest percentage of patients with glaucoma. Aside from the results being consistent with a big-box visual field, my patients are impressed with virtual reality and the ability to clean the unit for their safety.”
Olleyes has partnered with Keeler Limited (a Halma company) for US distribution of the VisuALL. Keeler specializes in diagnostic and magnification products for professionals in the optical and healthcare industries. The VisuALL’s productivity, portability, and ergonomic design align with Keeler’s mission to provide innovative instruments and services to professionals to execute work more efficiently, saving time and money.
Olleyes is a medical device company founded with the objective of revolutionizing eye-care. Our core product — VisuALL — is a Virtual Reality Platform designed for standardized and mobile assessment in eyecare.
We are focused on developing mobile and home-based diagnostic products for the early detection of and better management of eye disorders like Glaucoma, Diabetic Retinopathy, and Age-related Macular Degeneration. For more information, visit https://olleyes.com.
Name: Jorge Fernandez